Meeting Information - The second extraordinary general meeting of shareholders for 2025 will be held on September 9, 2025, at 14:30 [1] - The meeting will take place at the headquarters of Guangzhou Kingmed Diagnostics Group Co., Ltd. located at No. 10, Spiral Road, International Biological Island, Guangzhou [1] - Voting will be conducted through a combination of on-site and online methods using the Shanghai Stock Exchange's online voting system [1] Voting Procedures - Shareholders can vote via the Shanghai Stock Exchange's online voting system, either through the trading system or the internet voting platform [4][5] - The voting time for the online platform is from 9:15 to 15:00 on the day of the meeting [1] - Shareholders holding multiple accounts can aggregate their voting rights across all accounts [5] Agenda Items - The meeting will review several non-cumulative voting proposals, including amendments to the company's related party transaction management system, external investment management system, and external guarantee management system [2][3] - These proposals were previously approved in the board and supervisory meetings held on August 22, 2025 [2] Attendance - Shareholders registered by the close of trading on September 2, 2025, are eligible to attend the meeting [6] - Other attendees include company directors, senior management, and appointed lawyers [6] Registration Method - Shareholders must provide identification and relevant documentation to register for the meeting [6]

Core Viewpoint - Guangzhou Kingmed Diagnostics Group Co., Ltd. reported significant declines in key financial metrics for the first half of 2025, indicating potential challenges in its operational performance [1]. Financial Performance - Total revenue for the reporting period was approximately 2.997 billion RMB, a decrease of 22.78% compared to the previous year [1]. - The total profit for the period was a loss of approximately 109.61 million RMB, contrasting with a profit of about 96.88 million RMB in the same period last year, marking a decline of 213.14% [1]. - The net profit attributable to shareholders was a loss of approximately 84.81 million RMB, down 194.60% from a profit of about 89.65 million RMB in the previous year [1]. - The net cash flow from operating activities was not specified, but the weighted average return on net assets decreased by 2.29 percentage points to -1.21% [1]. - Basic and diluted earnings per share were both reported at -0.18 RMB, a decrease of 194.74% from 0.19 RMB in the previous year [1]. Shareholder Information - As of the end of the reporting period, the total number of shareholders was 42,347 [2]. - The top ten shareholders included Liang Yaoming, holding 16.02% of shares, and several investment funds and partnerships with varying percentages [2]. - Liang Yaoming is identified as the actual controller and holds significant stakes in multiple investment partnerships associated with the company [2].

证券代码：603882 证券简称：金域医学 公告编号：2025-034 广州金域医学检验集团股份有限公司 第四届董事会第七次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 广州金域医学检验集团股份有限公司（以下简称"公司"）第四届董事会第 七次会议于 2025 年 8 月 22 日在公司会议室以现场加通讯方式召开，会议通知已 于 2025 年 8 月 12 日以电子形式发出。会议由董事长梁耀铭先生主持，本次会议 应出席董事 9 名，实际出席董事 9 名。公司监事及高级管理人员列席本次会议。 会议召开符合《中华人民共和国公司法》和《公司章程》的有关规定。 二、董事会会议审议情况 出席本次会议的全体董事对本次会议的议案进行了认真审议，并以记名投票 表决方式通过以下决议： （二）审议通过《关于 2024 年度"提质增效重回报"行动方案的评估报告》 经审议，董事会认为公司编制的《关于 2024 年度"提质增效重回报"行动 方案的评估报告》能够真实、准确、完整地反映 2024 年具体举措实施情况。具 ...

证券代码：603882 证券简称：金域医学 公告编号：2025-036 广州金域医学检验集团股份有限公司 关于取消公司监事会并修订《公司章程》 及相关制度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 广州金域医学检验集团股份有限公司（以下简称"公司"）于 2025 年 8 月 司章程〉及相关议事规则的议案》及《关于修订公司部分治理制度的议案》，现 将相关情况公告如下： 一、取消监事会的情况 为贯彻落实新修订的《中华人民共和国公司法》（以下简称"《公司法》"）， 根据中国证监会《关于新 <公司法> 配套制度规则实施相关过渡期安排》等相关法 律、法规、规范性文件的规定及监管要求，公司拟取消监事会，由公司董事会审 计委员会行使《公司法》等法律法规规定的监事会职权。 二、修订《公司章程》及相关议事规则的情况 为进一步规范公司运作，完善公司治理，根据《上市公司章程指引》、 《上市 公司股东会规则》及《上海证券交易所股票上市规则》等相关法律、法规、规范 性文件的最新规定，结合公司实际情况，公司拟对《公司章程》、 《股东会议事规 ...

Summary of Key Points Core Viewpoint - The company has announced the provision for asset impairment to objectively and fairly reflect its financial status and operating results for the first half of 2025, in accordance with relevant accounting standards and policies [1][2]. Group 1: Asset Impairment Provision Overview - The company has recognized a total asset impairment provision of 272,349,303.43 RMB for the period from January to June 2025, which includes credit impairment losses of 272,474,717.40 RMB and asset impairment losses of -125,413.97 RMB [1]. - The credit impairment losses consist of 271,491,843.98 RMB from accounts receivable and 982,873.42 RMB from other receivables [1]. - The company employs an aging analysis method to assess expected credit losses based on credit risk characteristics [1]. Group 2: Specifics of Credit Impairment Losses - The company categorizes receivables into different groups based on credit risk characteristics, with Group One consisting of related party receivables and guarantees not subject to impairment provisions [1]. - Group Two includes other receivables, where the company applies an aging analysis method to calculate expected credit losses [1]. Group 3: Impact of Asset Impairment Provision - The provision for asset impairment is based on the principle of prudence and aligns with accounting standards, reflecting the company's actual situation and providing investors with more reliable and accurate financial information [2][3].

Core Viewpoint - The document outlines the working guidelines for the Board Secretary of Guangzhou Kingmed Diagnostics Group Co., Ltd, emphasizing the importance of compliance, responsibilities, and qualifications for the role to enhance corporate governance and information disclosure quality [2][4]. Group 1: General Provisions - The guidelines aim to promote standardized operations within the company and enhance the role of the Board Secretary [2]. - The Board Secretary is a senior management position responsible to the Board of Directors [2]. - The Board Secretary must adhere to laws, regulations, and the company's articles of association, bearing fiduciary and diligence obligations [2]. Group 2: Qualifications of the Board Secretary - The Board Secretary must possess at least a college degree and have over three years of experience in relevant fields [5]. - Required knowledge includes finance, taxation, law, finance, corporate management, and computer applications [5]. - A good personal character and professional ethics are essential, along with strong communication skills [5]. Group 3: Responsibilities of the Board Secretary - The Board Secretary is responsible for communication with regulatory bodies and ensuring compliance with reporting obligations [6]. - Duties include managing information disclosure, coordinating board meetings, and maintaining confidentiality of insider information [6][7]. - The role involves managing investor relations and ensuring effective communication with stakeholders [6][7]. Group 4: Appointment and Dismissal of the Board Secretary - The company must appoint a Board Secretary within three months of its initial public offering or the previous Secretary's departure [8]. - The Board Secretary cannot hold other positions in the controlling shareholder's unit, and independent directors cannot serve as Board Secretaries [8]. - Dismissal of the Board Secretary requires valid reasons, and the company must report such actions to regulatory bodies [8]. Group 5: Obligations and Support for the Board Secretary - The Board Secretary must act in the best interest of the company and shareholders, avoiding conflicts of interest [10]. - The company is required to provide necessary support and resources for the Board Secretary to fulfill their duties effectively [12]. - A dedicated securities affairs management department should be established to assist the Board Secretary [12]. Group 6: Accountability System for the Board Secretary - If the Board Secretary sells company shares within six months of purchase, the profits must be returned to the company [15]. - The Board Secretary and responsible personnel are liable for any misleading disclosures that result in investor losses [15]. - The company must cooperate with regulatory investigations if the Board Secretary violates laws or regulations [15].

General Principles - The investment management system aims to standardize the external investment behavior of Guangzhou Kingmed Diagnostics Group Co., Ltd., enhance management, mitigate risks, and protect the interests of investors [1] - External investment refers to the company's various forms of investment activities using monetary funds, equity, or assessed physical or intangible assets for future returns [1] Types of Investments - Investments are categorized into short-term and long-term based on duration, with short-term investments being those that can be liquidated within one year, and long-term investments exceeding one year [1] Investment Approval Authority - The company implements a professional management and hierarchical approval system for external investments, with specific thresholds for approval by the shareholders' meeting, board of directors, and general manager [2][4] - Shareholders' meeting approval is required for transactions exceeding 50% of total assets or net assets, or absolute amounts over 50 million yuan [2] - The board of directors can approve transactions exceeding 10% of total assets or net assets, or absolute amounts over 1 million yuan [2] Investment Management Organization - The shareholders' meeting and board of directors serve as decision-making bodies for external investments, while the general manager is responsible for implementing investment projects [8][9] - The finance department manages daily financial operations related to external investments, including funding and compliance with legal requirements [9] Investment Procedures - Short-term investment decisions involve pre-selection of investment opportunities by the general manager's office, with financial assessments provided by the finance department [11] - Long-term investment projects require preliminary evaluations and feasibility studies, followed by board approval [12] Financial Management and Auditing - The finance department is responsible for comprehensive financial records of external investments, ensuring compliance with accounting standards [49] - Annual checks of long-term and short-term investments are mandated, along with regular audits of subsidiaries [51][52] Amendments and Effectiveness - The investment management system is subject to amendments as per national laws and regulations, and it becomes effective upon approval by the shareholders' meeting [55]

广州金域医学检验集团股份有限公司 关联交易管理制度 （以下简称" 《证券法》"）、 广州金域医学检验集团股份有限公司 关联交易管理制度 第一章 总 则 第一条 为规范广州金域医学检验集团股份有限公司（以下简称"公司"）关 联交易行为，提高公司规范运作水平，保护投资者特别是中小投资者的合法权益， 根据《中华人民共和国公司法》 （以下简称" 《公司法》"）、 《中华人民共和国证券 法》 《上海证券交易所股票上市规则》 （以下简称"《上 《公开发行证券的公司信息披露内容与格式准则第 2 号——年度报告 市规则》"）、 《上海证券交易所上市公司自律监管指引第 5 号——交易与关联 的内容与格式》、 交易》等有关法律、法规和规范性文件，以及《广州金域医学检验集团股份有限 公司章程》（以下简称"公司章程"）的有关规定，制定本规则。 第二条 公司交易与关联交易行为应当合法合规，不得隐瞒关联关系，不得 通过将关联交易非关联化规避相关审议程序和信息披露义务。相关交易不得存在 导致或者可能导致公司出现被控股股东、实际控制人及其他关联人非经营性资金 占用、为关联人违规提供担保或者其他被关联人侵占利益的情形。 第三条 公司应当保证关 ...

广州金域医学检验集团股份有限公司 对外担保管理制度 第一章 总则 第一条 为了规范广州金域医学检验集团股份有限公司（下称"公司"）对外担保 行为，加强对外担保的管理，有效控制风险，保证公司资产的安全和完整，保护股东 和其他利益相关者的合法权益，根据《中华人民共和国公司法》（以下简称"《公司 法》"）、 《中华人民共和国证券法》 广州金域医学检验集团股份有限公司 对外担保管理制度 （以下简称"《证券法》"）、 《中华人民共和国民法典》 （以下简称"《民法典》"）、中国证监会《上市公司监管指引第 8 号——上市公司资 金往来、对外担保的监管要求》等相关法律法规及《广州金域医学检验集团股份有限 公司章程》（以下称"《公司章程》 "）的规定，制定本制度。 第二条 本制度所称子公司是指公司拥有实际控制权的控股子公司。 第三条 本制度所称担保是指公司对子公司、子公司对公司及各子公司相互之间、 公司及子公司为第三方提供的保证、抵押、质押及其他方式的担保。具体种类包括但 不限于借款担保、银行开立信用证、银行承兑汇票担保及开具保函的担保及法律规定 的其他担保方式等。 本制度所称"公司及其控股子公司的对外担保总额"是指包括公司对 ...

Core Points - The document outlines the insider information management system of Guangzhou Kingmed Diagnostics Group Co., Ltd, aimed at regulating insider information management, enhancing confidentiality, and preventing insider trading [1][2] - The system is established in accordance with relevant laws and regulations, including the Company Law and Securities Law of the People's Republic of China [1] Group 1: General Provisions - The system applies to the company, its departments, subsidiaries, and associated companies where the company holds a significant influence [1] - The Board of Directors is responsible for the registration and management of insider information personnel, with the Board Secretary organizing the implementation [2] - The company’s Audit Committee supervises the implementation of the insider information management system [2] Group 2: Insider Information and Personnel - Insider information refers to non-public information that significantly impacts the company's operations, finances, or stock market prices [3] - The system specifies that insider information personnel must maintain confidentiality and cannot disclose or trade based on insider information before it is publicly disclosed [5][6] Group 3: Registration Management - The company must maintain a record of insider information personnel, including their knowledge of insider information and the circumstances surrounding it [9][10] - Insider information personnel are required to fill out an insider information personnel record upon becoming aware of such information [11] Group 4: Confidentiality Management and Accountability - Insider information personnel have a responsibility to keep insider information confidential and must not leak or misuse it for personal gain [22][23] - The company will impose penalties on personnel who violate confidentiality obligations, including potential legal action [26][27] Group 5: Reporting and Documentation - The company must report insider information personnel records to the Shanghai Stock Exchange and the Guangdong Securities Regulatory Bureau within five trading days after the public disclosure of insider information [14][13] - Documentation related to insider information and personnel must be retained for at least ten years [11]